H.R. 8840
Fair Care Act of 2026
Sponsor: Bruce Westerman · 0 cosponsors
Official summary
No official summary yet.
Text of the bill
I Modernization of health savings accounts
A Modernization of health savings accounts and contributions
B Assistance to health savings accounts
II Improving Private Health Insurance
A Maintaining Protections for Patients with Preexisting Conditions
B Expanding Coverage Options
C Improving Commercial Health Insurance
III Competition, Transparency and Accountability
A Provider and Insurer Competition
B Price Transparency
C Prescription Drug Competition and Innovation
D Prescription Drug and Pharmacy Benefit Manager Transparency
(a) In general. The Comptroller General of the United States (referred to in this section as the Comptroller General) shall, in consultation with appropriate stakeholders, conduct a study on the role of pharmacy benefit managers.
(b) Permissible examination. In conducting the study required under subsection (a), the Comptroller General may examine various qualitative and quantitative aspects of the role of pharmacy benefit managers, such as the following:
(1) The role that pharmacy benefit managers play in the pharmaceutical supply chain.
(2) The state of competition among pharmacy benefit managers, including the market share for the Nation’s largest pharmacy benefit managers.
(3) The use of rebates and fees by pharmacy benefit managers, including—
(A) the extent to which rebates are passed on to health plans and whether such rebates are passed on to individuals enrolled in such plans;
(B) the extent to which rebates are kept by such pharmacy benefit managers; and
(C) the role of any fees charged by such pharmacy benefit managers.
(4) Whether pharmacy benefit managers structure their formularies in favor of high-rebate prescription drugs over lower-cost, lower-rebate alternatives.
(5) The average prior authorization approval time for pharmacy benefit managers.
(6) Factors affecting the use of step therapy by pharmacy benefit managers.
(c) Report. Not later than 3 years after the date of enactment of this Act, the Comptroller General shall submit to the Secretary of Health and Human Services, the Committee on Health, Education, Labor, and Pensions of the Senate, and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study conducted under subsection (a), including policy recommendations.
E Medicare and Medicaid Prescription Drug Reforms
F Medical Malpractice Reform
IV Medicare and Medicaid Reforms
A Medicaid Reforms
B Medicare Reforms
C Medicare Choice and Competition
D Telehealth Improvements and Expansion